/
Antifungal drugs Lec  18 Antifungal drugs Lec  18

Antifungal drugs Lec 18 - PowerPoint Presentation

bubbleba
bubbleba . @bubbleba
Follow
342 views
Uploaded On 2020-10-22

Antifungal drugs Lec 18 - PPT Presentation

30 12017 Dr Naza M Ali Antifungal Drugs Unlike bacteria fungi are eukaryotic Fungal infections are generally resistant to antibiotics used in the treatment of bacterial ID: 814721

mycoses amphotericin fungal drug amphotericin mycoses drug fungal antifungal fungi treatment agents systemic infections membrane effects drugs amphoteracin subcutaneous

Share:

Link:

Embed:

Download Presentation from below link

Download The PPT/PDF document "Antifungal drugs Lec 18" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Antifungal drugs

Lec

18

30 -1-2017

Dr.

Naza

M. Ali

Slide2

Slide3

Antifungal Drugs

Unlike bacteria, fungi are eukaryotic.

Fungal infections are generally resistant to

antibiotics used in the treatment of bacterial

infections, and conversely, bacteria are resistant to

antifungal agents.

Infectious diseases caused by fungi are called mycoses, they are often chronic in nature.

Slide4

Mycoses divided into:

Cutaneous

mycoses

:

Infection are superficial and only involve the

(skin, hair, nails).

Subcutaneous mycoses

:

Fungi that grow in soil and on vegetation and

are introduced into subcutaneous tissue

through trauma.

Slide5

Systemic mycoses

:

I

nfections result from inhalation of the spores

of dimorphic fungi that have their saprophytic

mold forms in the soil.

are most

difficult to treat which are often life

threatening.

Slide6

Mechanism of drug acting on fungi

Alter cell membrane permeability

2. Block nucleic acid synthesis

3. Disrupt microtubule functions

Slide7

Drugs for subcutaneous

and systemic fungal infections

1.

Amphoteracin

B

2.

Flucytosine

5-FC

3.

Azole

antifungal agents:

-

Ketoconazole

-

Fluconazole

-

Itraconazole

-

Voriconazole

-

Posaconazole

(new)

Slide8

4.

Echinocandins

-

Caspofungin

-

Micafungin

Slide9

Amphoteracin

B

Is a naturally occurring

polyene

macrolide

antibiotic produced by

Streptomyces

nodosus

.

Is the drug of choice for the treatment of life-threatening systemic mycoses.

Conventional

amphotericin

(

amphotericin

B

deoxycholate

, the

nonlipid

formulation)

has undergone several formulation improvements to reduce the incidence of side effects

(

nephrotoxicity).

Slide10

The drug is used in combination with

flucytosine

to achieve more rapid sterilization of the CSF.

Amphotericin

B is either fungicidal or

fungistatic

,

depending on organism and concentration of the drug.

It is often used for initial induction regiments before follow up treatment with an

azole

.

Slide11

It has

widest antifungal agents spectrum

than any

agents and the drug of choice for systemic most

infections caused by

Aspergillus

,

Blastomyces

, Candida

albicans

,

Cryptococcus,

Histoplasma

and

Mucor

.

it is usually given by slow IV infusion.

In case of fungal meningitis( by

intrathecal

route).

Local administration in treatment of

mycotic

corneal ulcer

Slide12

Slide13

Mechansim

of action of

Amphoteracin

B

I

s a

polyene

macrolide related to

nystatin

polyenes

are molecules with both hydrophilic &

lipophilic characteristics.

Several amphotericin B molecules bind to

ergosterol

in the plasma membranes of fungal cells, and cause

the formation of artificial pores (channels).

The pores disrupt membrane function, allowing

electrolytes and small molecules to leak from the cell,

resulting in cell death.

Slide14

Slide15

Resistance:

Fungal resistance, is associated with decreased

ergosterol

content of the fungal membrane.

Slide16

Pharmacokinetics:

Amphotericin B

is used by slow, (IV) infusion

Is insoluble in water, and injectable preparations require the addition of sodium

deoxycholate

, which produces a soluble colloidal dispersion.

The more dangerous

intrathecal

route is chosen for the treatment of meningitis.

Slide17

Slide18

Slide19

Amphotericin B has also been formulated with a

variety of artificial lipids that form liposomes

.

Amphotericin B is extensively bound to plasma protein.

Inflammation favors penetration into various body fluids.

Slide20

Adverse

effects

Amphotericin B has a low therapeutic index

A total adult daily dose should not exceed

1.5 mg/kg

Small test doses are usually administered to avoid

anaphylaxis or convulsions

Slide21

Fever & chills

:

These occur most commonly 1-3 hours after

starting IV, but they usually subside with repeated

administration of the drug.

Premedication with an antipyretic or a corticosteroid

helps to prevent problem.

Slide22

2. R

enal impairment

:

Azotemia (elevated blood urea)

adequate hydration can decrease its severity.

3. Hypotension:

A shock-like fall in blood pressure

4. Anemia

5. Neurologic effects

Slide23